Advertisement

Neuromyopathies in the Critically Ill

  • Francis C. Cordova
  • Maria Roselyn C. Lim
  • Gerard J. Criner
Chapter

Abstract

After studying this chapter, you should be able to: Be aware of the different neuromuscular disorders that are encountered in the ICU. Know the effects of neuromuscular dysfunction on the respiratory system. Know the proper initial evaluation and management of patients with neuromuscular dysfunction and respiratory failure. Be aware of the various therapies used to treat neuromuscular disorders that are most commonly encountered in the ICU.

Keywords

Amyotrophic Lateral Sclerosis Forced Vital Capacity Acute Respiratory Failure Amyotrophic Lateral Sclerosis Patient Noninvasive Positive Pressure Ventilation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

REFERENCES

  1. 1.
    Johnson DC, Kazemi H. Central control of ventilation in neuromuscular disease. Clin Chest Med. 1994;15:607-617.PubMedGoogle Scholar
  2. 2.
    Riley D, Santiago T, Daniele R, et al. Blunted respiratory drive in congenital myopathy. Am J Med. 1977;63:459-466.PubMedCrossRefGoogle Scholar
  3. 3.
    Begin R, Bureau MA, Lupien L, et al. Control and modulation of respiration in Steinert’s yotonic dystrophy. Am Rev Respir Dis. 1980;121:281-289.PubMedGoogle Scholar
  4. 4.
    Demedts M, Beckers J, Rochette F, et al. Pulmonary function in moderate neuromucular disease without respiratory complaints. Eur J Respir Dis. 1982;63:62-67.PubMedGoogle Scholar
  5. 5.
    Vincken W, Elleker MG, Cosio M. Determinants of respiratory muscle weakness in stable neuromuscular disorders. Am J Med. 1987;82:53-58.PubMedCrossRefGoogle Scholar
  6. 6.
    Bye PTP, Ellis ER, Issa FG, et al. Respiratory failure and sleep in neuromuscular disease. Thorax. 1990;45:241-247.PubMedCrossRefGoogle Scholar
  7. 7.
    Estenne M, Heilporn A, Delhez L, et al. Chest wall stiffness in patients with chronic respiratory muscle weakness. Am Rev Respir Dis. 1983;128:1002-1007.PubMedGoogle Scholar
  8. 8.
    Braun NMT, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyosities and other proximal myopathies. Thorax. 1983;38:616-623.PubMedCrossRefGoogle Scholar
  9. 9.
    Sherman M, Kleopa K, Neal B, et al. Noninvasive ventilation improves survival and slows decline of pulmonary function in patients with amyotrophic lateral sclerosis (abstract). Am J Respir Crit Care Med. 1999;159:A295.Google Scholar
  10. 10.
    Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Lancer Neurol. 2006;5(2):140-7.CrossRefGoogle Scholar
  11. 11.
    Schiffman PL, Belsh JM. Effect of inspiratory resistance and theophylline on respiratory muscle strength in patients with amyotrophic lateral sclerosis. Am Rev Respir Dis. 1989;139: 1418-1423.PubMedGoogle Scholar
  12. 12.
    Ropper AH. The Guillain–Barré syndrome. N Engl J Med. 1992;326(6):1130-1136.PubMedGoogle Scholar
  13. 13.
    Ropper AH, Kehne SM. Guillain-Barré syndrome: management of respiratory failure. Neurology. 1985;35:1662-1665.PubMedCrossRefGoogle Scholar
  14. 14.
    Chevrolet J, Deleamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain- Barré syndrome. Am Rev Respir Dis. 1991;144:814-818.PubMedCrossRefGoogle Scholar
  15. 15.
    Orlikowski D, Sharshar T, Porcher R, Annane D, Raphael JC, Clair B. Prognosis and risk factors of early onset pneumonia in ventilated patients with Guillain-Barre syndrome. Intensive Care Med. 2006;32:1962-1969.PubMedCrossRefGoogle Scholar
  16. 16.
    Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol. 2001;58:893-98.PubMedCrossRefGoogle Scholar
  17. 17.
    Sharshar T, Chevret S, Bourdain F, Raphael JC. Early predictors of mechanical ventilation in Guillain-Barre syndrome. Crit Care Med. 2003;31:278-83.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaida K, Kusunoki S, Kansaki M, Kamakura K, Motoyoshi K, Kanazawa I. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barre syndrome. Neurology. 2004;62:821-24.PubMedCrossRefGoogle Scholar
  19. 19.
    Durand MC, Porcher R, Orlikowski D, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barre syndrome: a prospective study. Lancet Neurol. 2006;5:1021-28.PubMedCrossRefGoogle Scholar
  20. 20.
    McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain–Barré syndrome: analysis of prognostic factors and the effects of plasmapheresis. Ann Neurol. 1988;23:347-353.PubMedCrossRefGoogle Scholar
  21. 21.
    Plasma Exchange/Sandoglobulin Guillain-Barré Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Lancet. 1997;349:225-230.CrossRefGoogle Scholar
  22. 22.
    van der Meche FGA, Schmitz PIM, the Dutch Guillain–Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. N Engl J Med. 1992;326:1123-1129.PubMedCrossRefGoogle Scholar
  23. 23.
    Kleyweg RP, van der Meche FG, Meulstee J. Treatment of Guillain-barre syndrome with high dose gammaglobulin. Neurology. 1988;38:1639-41.PubMedCrossRefGoogle Scholar
  24. 24.
    Hughes RAC, Swan AV, Raphael JC, Annane D, Koningsveld RV, van Dorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain. 2007;130:2245-3357.PubMedCrossRefGoogle Scholar
  25. 25.
    Hughes RAC, Swan AC, van Koningsveld R, van Doorn P. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2007;(4):ISSN: 1469-493X, Accession: 16625544.Google Scholar
  26. 26.
    De Jonghe B, Cook D, Sharshar T, et al. Acquired neuromuscular disorders in critically ill patients: a systematic review. Intensive Care Med. 1998;24:1242-50.PubMedCrossRefGoogle Scholar
  27. 27.
    Khan J, Harrison TB, Rich MM, Moss M. Early development of critical illness myopathy and neuropathy in patient with severe sepsis. Neurology. 2006;67:1421-1425.PubMedCrossRefGoogle Scholar
  28. 28.
    Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences: a cohort study in septic patients. Intensive Care Med. 2001;27:1288-1296.PubMedCrossRefGoogle Scholar
  29. 29.
    Schweickert WD, Hall J. ICU-acquired weakness. Chest. 2007;131:1541-1549.PubMedCrossRefGoogle Scholar
  30. 30.
    De Letter MA, van Doorn PA, et al. Critical Illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol. 2000;106:206-213.PubMedCrossRefGoogle Scholar
  31. 31.
    Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuropathy. J Neurol. 2005;252: 343-351.PubMedCrossRefGoogle Scholar
  32. 32.
    Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64:1348-53.PubMedCrossRefGoogle Scholar
  33. 33.
    Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.PubMedCrossRefGoogle Scholar
  34. 34.
    Van der Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-66.PubMedCrossRefGoogle Scholar
  35. 35.
    Van de Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.CrossRefGoogle Scholar
  36. 36.
    Hermans G, Wilmer A, Meerseman W, Milants I, Wouters PJ, Bobbaers H, Bruyninckx F, Van den Berghe. Impact of intensive insulin therapy on neuromuscular complication and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med. 2007;175:480-489.PubMedCrossRefGoogle Scholar
  37. 37.
    Allen DC, Arunnachalam R, Mills KR. Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy. Muscle Nerve. 2007;37(1):14-22CrossRefGoogle Scholar
  38. 38.
    Rich MM, Pinter MJ. Crucial role of sodium channell fast inactivation in muscle fiber inexcitability in a rat model of critical illness myopathy. J Physiol. 2003;547:555-66.PubMedCrossRefGoogle Scholar
  39. 39.
    Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, et al. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patient. Crit Care Med. 2005;33:349-354.PubMedCrossRefGoogle Scholar
  40. 40.
    De Jonghe B, Bastuji-Garin S, Sharshar T, et al. Does ICU acquired paresis lengthen weaning from mechanical ventilation. Intensive Care Med. 2004;30:1117-1121.PubMedCrossRefGoogle Scholar
  41. 41.
    Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683-93.PubMedCrossRefGoogle Scholar
  42. 42.
    Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care. 2005;11:126-132.PubMedCrossRefGoogle Scholar
  43. 43.
    Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-Musk antibodies in generalized seronegative myasthenia gravis. Brain. 126:2304-2311.Google Scholar
  44. 44.
    Sanders DB. K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978-1980.PubMedCrossRefGoogle Scholar
  45. 45.
    Quareshi Al, Choundry MA, Mohammad Y, Chua HC, et al. Respiratory failure as a first presentation of myasthenia gravis. Med Sci Monitor. 2004;10(12):CR684-CR689.Google Scholar
  46. 46.
    Watanabe A, Watanabe T, Obama T, et al. Prognostic factors for myasthenic crises after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 2004;127:868-876.PubMedCrossRefGoogle Scholar
  47. 47.
    Gajdos P, Tranchant C, Clair B, et al. Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789-796.PubMedCrossRefGoogle Scholar
  48. 48.
    Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crises. Neurology. 1999;52:629-632.PubMedCrossRefGoogle Scholar
  49. 49.
    Seneviratne J, Mandrekar J, Wijdicks EFM, Rabinstein AA. Noninvasive ventilation in myasthenia crisis. Arch Neurol. 2008;65(1):54-58.PubMedCrossRefGoogle Scholar
  50. 50.
    Varelas PN, Chua HC, Natterman J, Barmadia L, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med. 2002;30:2663-2668.PubMedCrossRefGoogle Scholar
  51. 51.
    Juel VC. Myasthenia gravis: management of myasthenic crises and perioperative care. Semin Neurol. 2004;24:1, 75-81.PubMedCrossRefGoogle Scholar
  52. 52.
    Seneviratne J, Mandrekar J, Wijdicks FM, Rabinstein AA. Predictors of extubation in myasthenic crisis. Arch Neurol. 2008;65(7):929-933.PubMedCrossRefGoogle Scholar

ADDITIONAL READING

  1. Rabinstein AA. Update on respiratory management of critically ill neurologic patients. Curr Neurol Neurosci Rep. 2005;5:476-82.PubMedCrossRefGoogle Scholar
  2. Kelly BJ, Luce JM. The diagnosis and management of neuromuscular disease causing respiratory failure. Chest. 1991;99:1485-1494.PubMedCrossRefGoogle Scholar
  3. Unterborn JN, Hill NS. Options for mechanical ventilation in neuromuscular diseases. Clin Chest Med. 1994;15(4):765-781.PubMedGoogle Scholar
  4. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care. 2005;11:126-132.PubMedCrossRefGoogle Scholar
  5. Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:7-15.PubMedCrossRefGoogle Scholar
  6. Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Seminars in Neuro. 2004;24:75-81.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Francis C. Cordova
    • 1
  • Maria Roselyn C. Lim
    • 2
  • Gerard J. Criner
    • 3
  1. 1.Department of Internal Medicine, Division of Pulmonary and Critical CareTemple University School of MedicinePhiladelphiaUSA
  2. 2.Department of Neurology/Internal MedicineSt. Mary’s Medical CenterLanghorneUSA
  3. 3.Pulmonary and Critical Care Medicine and Temple Lung CenterTemple University School of MedicinePhiladelphiaUSA

Personalised recommendations